aTyr plunges as lung disease drug misses main goal in late-stage study

Shares of drug developer aTyr Pharma ATYR.O fall 83% to $1.01 premarket

Co says its experimental drug efzofitimod did not meet the main goal in a late-stage study in patients with pulmonary sarcoidosis

Pulmonary sarcoidosis is an inflammatory condition affecting the lungs and lymph nodes

ATYR says it plans to engage with the U.S. FDA to determine the path forward for the drug

Up to last close, stock up 66.6% YTD